FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • Tuesday
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid TechnologyGlobeNewsWire • 10/29/24
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024GlobeNewsWire • 10/28/24
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic DiseasesGlobeNewsWire • 10/18/24
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent OfficeGlobeNewsWire • 10/16/24
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual SummitGlobeNewsWire • 10/11/24
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based TechnologyGlobeNewsWire • 09/12/24
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/06/24
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based TechnologyGlobeNewsWire • 08/20/24
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid TechnologyGlobeNewsWire • 06/25/24
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent OfficeGlobeNewsWire • 04/11/24
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USAGlobeNewsWire • 04/04/24
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of LupusGlobeNewsWire • 03/28/24
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes TreatmentPRNewsWire • 03/19/24